<i>BRAF</i><sup>V600E</sup>基因突变在甲状腺癌中的临床应用研究进展

姚小芹; 王辉; 姚小芹; 王辉

doi:10.3760/cma.j.issn.1673-4114.2012.02.006

[1]

Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer, 2005, 12(2): 245-262. doi: 10.1677/erc.1.0978

[2]

Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab, 2009, 94(5): 1612-1617. doi: 10.1210/jc.2008-2390

[3]

Frasca F, Nucera C, Pellegriti G, et al. BRAF^(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer, 2008, 15(1): 191-205. doi: 10.1677/ERC-07-0212

[4]

Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancaer. J clin Endocrinol Metab, 2005, 90(12): 6373-6379. doi: 10.1210/jc.2005-0987

[5]

Lupi C, Giannini R, Ugolini C, et al. Association of BRAF^V600E mutation with poor clinicopathologic outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab, 2007, 92(1): 4085-4090.

[6]

郝丽君, 方军初, 洪智慧, 等. ^99mTcO₄^-核素显像联合超声检查对甲状腺结节的鉴别诊断价值.中华医学杂志, 2011, 91(45): 3210-3213. doi: 10.3760/cma.j.issn.0376-2491.2011.45.012

[7]

Sclabas GM, Staerkel GA, Shapiro SE, et al. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J of Surg, 2003, 186(6): 702-709. doi: 10.1016/j.amjsurg.2003.08.015

[8]

Xing M, Tufano RP, Tufaro AP, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab, 2004, 89(6): 2867-2872. doi: 10.1210/jc.2003-032050

[9]

Cradic KW, Milosevic D, Rosenberg AM, et al. Mutant BRAF^T1799A can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status. J Clin Endocrinol Metab, 2009, 94(12): 5001-5009. doi: 10.1210/jc.2009-1349

[10]

Ito Y, Kudo T, Kobayashi K, et al. Prognostic factors for recurrence of papillary thyroid carcinoma in the lymph nodes, lung, and bone: analysis of 5, 768 patients with average 10-year follow-up[J/OL]. World J Surg, 2012[2012-01-22]. http://www.springerlink.com/content/w642210502436521. [published online ahead of print July 20, 2012].

[11]

Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V600E, in papillary thyroid cancers. J Clin Endocrinol Metab, 2003, 88(9): 4393-4397. doi: 10.1210/jc.2003-030305

[12]

Barollo S, Pennelli G, Vianello F, et al. BRAF in primary and recurrent papillary thyroid cancers: the relationship with ¹³¹I and 2-[¹⁸F] fluoro-2-deoxy-D-glucose uptake ability. Eur J Endocrinol, 2010, 163(4): 659-663.

[13]

Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, et al. The BRAF^V600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer. Cancer Res, 2009, 69(21): 8317-8325. doi: 10.1158/0008-5472.CAN-09-1248

[14]

Feine U, Lietzenmayer R, Hanke JP, et al. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med, 37(9): 1468-1472.

[15]

Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase Ⅱ trial of sorafenib in advanced thyroid cancer. J Clin Oncol, 2008, 26(29): 4714-4719. doi: 10.1200/JCO.2008.16.3279

[16]

Kloos RT, Ringel MD, Knopp MV, et al. Phase Ⅱ trial of sorafenib in metastatic thyroid cancer. J Clin Oncol, 2009, 27(10): 1675-1684. doi: 10.1200/JCO.2008.18.2717

[17]

Hahn O, Stadler W. Sorafenib. Curr Opin Oncol, 2006, 18(6): 615-621. doi: 10.1097/01.cco.0000245316.82391.52